RATIONALE: Ketamine induces, in both humans and rodents, behaviours analogous to some of the symptoms of schizophrenia. OBJECTIVES: To utilise pharmacological magnetic resonance imaging (phMRI) techniques that identify changes in blood-oxygenation-level-dependent (BOLD) contrast to determine the temporal and spatial neuronal activation profile of ketamine in the rat brain. METHOD: To obtain a pharmacodynamic profile of the drug, we assessed changes in locomotor activity after vehicle and 10 and 25 mg/kg ketamine. Separate animals were then anaesthetised and placed in a 4.7-T magnetic resonance (MR) system before receiving the same doses of ketamine during serial MR image acquisition. Subsequent statistical parametric mapping of the main effect of the drug was then undertaken to identify changes in BOLD contrast. Levels of gamma-aminobutyric acid (GABA) and dopamine (DA) in brain areas showing localised changes in BOLD contrast were then assessed via microdialysis. RESULTS: Both doses of ketamine produced increases in BOLD image contrast in frontal, hippocampal, cortical and limbic areas. A further investigation of the release of DA and its metabolites in the nucleus accumbens, both in anaesthesised and freely moving rats, corroborated these findings. However, an investigation of GABA and DA levels in the ventral pallidum gave no indication of changes in activity. CONCLUSIONS: Ketamine produced localised dose-dependent alterations in BOLD MR signal, which correlate with the pharmacodynamic profile of the drug. These results can be, at least, partially substantiated with complementary techniques but consideration must be given to the input function applied to the MR signal and the use of anaesthesia during phMRI experimentation.
RATIONALE: Ketamine induces, in both humans and rodents, behaviours analogous to some of the symptoms of schizophrenia. OBJECTIVES: To utilise pharmacological magnetic resonance imaging (phMRI) techniques that identify changes in blood-oxygenation-level-dependent (BOLD) contrast to determine the temporal and spatial neuronal activation profile of ketamine in the rat brain. METHOD: To obtain a pharmacodynamic profile of the drug, we assessed changes in locomotor activity after vehicle and 10 and 25 mg/kg ketamine. Separate animals were then anaesthetised and placed in a 4.7-T magnetic resonance (MR) system before receiving the same doses of ketamine during serial MR image acquisition. Subsequent statistical parametric mapping of the main effect of the drug was then undertaken to identify changes in BOLD contrast. Levels of gamma-aminobutyric acid (GABA) and dopamine (DA) in brain areas showing localised changes in BOLD contrast were then assessed via microdialysis. RESULTS: Both doses of ketamine produced increases in BOLD image contrast in frontal, hippocampal, cortical and limbic areas. A further investigation of the release of DA and its metabolites in the nucleus accumbens, both in anaesthesised and freely moving rats, corroborated these findings. However, an investigation of GABA and DA levels in the ventral pallidum gave no indication of changes in activity. CONCLUSIONS:Ketamine produced localised dose-dependent alterations in BOLD MR signal, which correlate with the pharmacodynamic profile of the drug. These results can be, at least, partially substantiated with complementary techniques but consideration must be given to the input function applied to the MR signal and the use of anaesthesia during phMRI experimentation.
Authors: Golam M I Chowdhury; Kevin L Behar; William Cho; Monique A Thomas; Douglas L Rothman; Gerard Sanacora Journal: Biol Psychiatry Date: 2011-12-09 Impact factor: 13.382
Authors: Sakthivel Sekar; M Verhoye; J Van Audekerke; G Vanhoutte; Andrew S Lowe; Andrew M Blamire; Thomas Steckler; A Van der Linden; Mohammed Shoaib Journal: Psychopharmacology (Berl) Date: 2010-11-20 Impact factor: 4.530
Authors: S Sekar; E Jonckers; M Verhoye; R Willems; J Veraart; J Van Audekerke; J Couto; M Giugliano; K Wuyts; S Dedeurwaerdere; J Sijbers; C Mackie; L Ver Donck; T Steckler; A Van der Linden Journal: Psychopharmacology (Berl) Date: 2013-01-25 Impact factor: 4.530
Authors: Jennifer Li; Keita Ishiwari; Michael W Conway; Jennifer Francois; John Huxter; John P Lowry; Adam J Schwarz; Mark Tricklebank; Gary Gilmour Journal: Neuropsychopharmacology Date: 2014-01-20 Impact factor: 7.853
Authors: Inna Gaisler-Salomon; Gretchen M Miller; Nao Chuhma; Sooyeon Lee; Hong Zhang; Farhad Ghoddoussi; Nicole Lewandowski; Stephen Fairhurst; Yvonne Wang; Agnès Conjard-Duplany; Justine Masson; Peter Balsam; René Hen; Ottavio Arancio; Matthew P Galloway; Holly M Moore; Scott A Small; Stephen Rayport Journal: Neuropsychopharmacology Date: 2009-06-10 Impact factor: 7.853
Authors: Antonio Napolitano; Khalid Shah; Mirjam I Schubert; Veronica Porkess; Kevin C F Fone; Dorothee P Auer Journal: Schizophr Bull Date: 2013-05-13 Impact factor: 9.306